论文部分内容阅读
目的：探讨前列腺癌（ Ｐ Ｃａ） 患者治疗前血清前列腺特异性抗原（ Ｐ Ｓ Ａ） 水平对评估 Ｐ Ｃａ 预后的价值。方法：采用放射免疫分析法检测２４ 例预后良好和３３ 例预后不良的 Ｐ Ｃａ 患者治疗前的血清 Ｐ Ｓ Ａ 水平。结果：两组病例治疗前血清 Ｐ Ｓ Ａ 水平显著高于正常对照组（ Ｐ＜ ０ ．０１） ， Ｐ Ｃａ 患者预后不良组治疗前血清 Ｐ Ｓ Ａ 水平亦显著高于预后良好组（ Ｐ＜ ０ ．０１） 。结论： Ｐ Ｃａ 患者治疗前血清 Ｐ Ｓ Ａ 水平对评估其预后具有一定价值。
Objective: To investigate the value of serum prostate-specific antigen (P S A) level before treatment in patients with prostate cancer (P Ca) to assess the prognosis of P Ca. Methods: Serum P S A levels in 24 patients with good prognosis and 33 poor prognosis of P Ca before treatment were detected by radioimmunoassay. Results: Before treatment, serum P S A level in both groups was significantly higher than that in the normal control group (P <0.01). The P S A level in patients with poor prognosis of P Ca group was also significantly higher than that in the good prognosis group (P <0. 01) .01). Conclusion: The level of serum P S A in patients with P Ca prior to treatment is of value in assessing the prognosis.